CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
神经内分泌肿瘤(NEN)是一组异质性肿瘤,临床表现和预后各不相同。若具备手术条件,手术是最有效且往往可治愈的治疗方式。然而,许多NEN患者确诊时已处于局部晚期或已发生转移,因此仍需采用其他局部或全身治疗。基于CAR-T 细胞的免疫治疗在多种癌症中已显示出令人瞩目的疗效。本叙述性综述旨在分析CAR-T 用于NEN的现有数据,涵盖临床前和临床研究。研究人员广泛检索了相关资料来源,包括正式发表的全文、国际会议摘要以及全球登记的临床试验。细胞系和动物模型开展的临床前研究提示,CAR-T 细胞对NEN具有显著治疗作用。正在开展和未来的临床试验将进一步明确这类疗法在高度侵袭性NEN患者中的潜在作用。
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with variable clinical presentation and prognosis. Surgery, when feasible, is the most effective and often curative treatment.
However, NENs are frequently locally advanced or already metastatic at diagnosis. Consequently, additional local or systemic therapeutic approaches are required. Immunotherapy, based on chimeric antigen receptor T cells (CAR-T), is showing impressive results in several cancer treatments. The aim of this narrative review is to analyze the available data about the use of CAR-T in NENs, including studies in both preclinical and clinical settings.
We performed an extensive search for relevant data sources, comprising full-published articles, abstracts from international meetings, and worldwide registered clinical trials. Preclinical studies performed on both cell lines and animal models indicate a significant therapeutic effect of CAR-T cells in NENs. Ongoing and future clinical trials will clarify the possible role of these drugs in patients with highly aggressive NENs.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。